Differential activation of dendritic cells by toll-like receptors causes diverse differentiation of naïve CD4+ T cells from allergic patients

S. Deifl1,2, C. Kitzmüller1,2, P. Steinberger3, M. Himly4, B. Jahn-Schmid2, G. F. Fischer5, G. J. Zlabinger3 & B. Bohle1,2

1Christian Doppler Laboratory for Immunomodulation, Medical University of Vienna; 2Department of Pathophysiology and Allergy Research, Medical University of Vienna; 3Institute of Immunology, Medical University of Vienna, Vienna; 4Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular Biology, University of Salzburg, Salzburg; 5Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria

To cite this article: Deifl S, Kitzmüller C, Steinberger P, Himly M, Jahn-Schmid B, Fischer GF, Zlabinger GJ, Bohle B. Differential activation of dendritic cells by toll-like receptors causes diverse differentiation of naïve CD4+ T cells from allergic patients. Allergy 2014; 69: 1602–1609.

Keywords
cytokines; dendritic cells; innate immune system; T-cell differentiation; toll-like receptor.

Abstract
Background: To avert the differentiation of allergen-specific Th2 cells in atopic individuals is a major goal in the prevention and therapy of IgE-mediated allergy. We aimed to compare different toll-like receptor (TLR) agonists regarding their effects on antigen-presenting cells and the differentiation of naïve T cells from allergic patients.

Methods: Monocytes and monocyte-derived dendritic cells (mdDC) from allergic patients were stimulated with Pam3CSK4 (TLR1/2 ligand), FSL-1 (TLR2/6 ligand), monophosphoryl lipid (MPL)-A, lipopolysaccharide (LPS, both TLR4 ligands), and flagellin (TLR5 ligand). Allergen uptake and upregulation of CD40, CD80, CD83, CD86, CD58, CCR7 and PD-L1 were analyzed by flow cytometry. Functional maturation of mdDC was tested in mixed leukocyte reactions, and the synthesis of proinflammatory cytokines, IL-10 and members of the IL-12 family was assessed. TLR-ligand-activated mdDC were used to stimulate naïve CD4+ T cells, and cytokine responses were assessed in supernatants and intracellularly.

Results: All TLR ligands except flagellin enhanced allergen uptake. All TLR ligands induced functional maturation of mdDC with differential expression of surface molecules and cytokines and promoted the differentiation of IFN-γ-producing T cells. LPS-matured mdDC exclusively induced Th1-like responses, whereas mdDC stimulated with the other TLR ligands induced both Th1- and Th0-like cells. Pam3CSK4 and flagellin additionally induced Th2-like cells. Th1-like responses were associated with higher expression levels of co-stimulatory molecules, PD-L1, IL-6, TNF-α, and IL-12p70. None of the TLR-ligand-stimulated mdDC induced IL-10- or IL-17-producing T cells.

Conclusion: Different TLR ligands differently influence T-cell responses due to varying activation of the three signals relevant for T-cell activation, that is, antigen presentation, co-stimulation and cytokine milieu.

IgE-mediated hypersensitivity results from an overwhelming Th2 response leading to the production of IgE antibodies (Abs), which then mediate allergic symptoms. In contrast, the response to allergens in nonallergic individuals is characterized by Th0/Th1 responses and regulatory T (Treg) cells (1, 2). Hence, the restoration of a balanced allergen-specific T-cell response in atopic individuals is a major goal

Abbreviations
APC, antigen-presenting cell; DC, dendritic cell; LPS, lipopolysaccharide; mdDC, monocyte-derived dendritic cells; MLR, mixed leukocyte reaction; MPL, monophosphoryl lipid; PD-L1, programmed death ligand 1; SIT, allergen-specific immunotherapy; SN, supernatant; TCC, T-cell clone; Th, T helper; TLR, toll-like receptor.
in the prevention and treatment of allergic diseases. Indeed, successful allergen-specific immunotherapy (SIT) has been associated with the modulation of allergen-specific Th2 toward Th0/Th1 and Treg cells (3). The differentiation of naïve T cells into effector cells requires three signals. Antigen-specific activation of the T-cell receptor represents signal 1 and is mediated by antigen-derived peptides loaded to MHC class II molecules. Co-stimulatory molecules expressed on the surface of professional antigen-presenting cells (APC), for example, dendritic cells (DC), represent signal 2. Finally, APC-derived cytokines (signal 3) play a decisive role in skewing CD4+ T-cell responses toward a particular effector subset. For example, the presence of members of the IL-12 family and/or IL-18 promotes the induction of Th1 cells, whereas IL-10 promotes the differentiation of Treg cells (4-6).

Stimulating toll-like receptors (TLR) that recognize pathogen-associated molecular patterns is one possibility to promote Th1 responses (7). Therefore, TLR ligands have been considered as immunomodulators in SIT. In this respect, MPL-A, a nontoxic derivative of LPS targeting surface-expressed TLR4, and immunostimulatory DNA sequences of bacterial origin targeting intracellular TLR9 have been clinically evaluated (8-11). Both TLR ligands have been demonstrated to induce Th1-like cytokines in PBMC from allergic individuals (12, 13). Today, allergy vaccines containing MPL-A are routinely used for SIT of adults and children (14, 15) whereas the use of immunostimulatory DNA for allergy treatment is currently not pursued. Besides TLR4, TLR1, TLR2, TLR5, and TLR6 are located on the surface of various types of professional APC, namely myeloid DC, monocytes, and Langerhans cells (16). Monocyte-derived (md)DC from allergic donors have been shown to express high levels of TLR2, TLR4, TLR5 and TLR6 and to respond to TLR activation like mdDC from nonallergic individuals (16). However, the effects of mdDC stimulated with different TLR ligands on T-cell differentiation have not been compared yet.

To address this issue, mdDC from allergic patients were stimulated with Pam3CSK4 (TLR1/2), FSL-1 (TLR2/6), lipopolysaccharide (LPS), monophosphoryl lipid (MPL)-A (both TLR4 ligands), and flagellin from S. typhimurium (TLR5). Allergen uptake was studied by employing fluorescence-labeled Bet v 1, the major birch pollen allergen. The expression of the maturation marker CD83, co-stimulatory molecules (CD40, CD80, CD86), and the homing factor CCR7 was analyzed. Thereafter, cells were stained with fluorescence-labeled Bet v 1, the major birch pollen allergen. The expression of the maturation marker CD83, co-stimulatory molecules (CD40, CD80, CD86), and the homing factor CCR7 was analyzed. We also included the analysis of CD58 expression levels because CD2-CD58 interaction has been shown to induce regulatory T cells (17). Furthermore, the expression of the negative regulatory molecule programmed death ligand 1 (PD-L1) was assessed as PD-L1 expression has been linked to the ability to promote Th1-like responses (18). TLR-ligand-induced levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α), different members of the IL-12 family (IL-12p70, IL-23, IL-27), and IL-10 were determined. Finally, the polarizing capacity of TLR-ligand-activated mdDC was tested in co-cultures with naïve CD4+ T cells.

Materials and methods

Reagents

FSL-1, Pam3CSK4, MPL-A, LPS (source: E. coli 0111:B4), and flagellin from S. typhimurium were purchased from InvivoGen, San Diego, CA, USA. Recombinant Bet v 1.0101 (referred to as Bet v 1) was purchased from Biomay AG, Vienna, Austria. Endotoxin levels were below 1 EU/mg for each reagent. Labeling of Bet v 1 with pHrodo succinimidyl ester (Invitrogen, Carlsbad, CA, USA) was performed as described previously (19).

Allergic individuals

Heparinized blood was obtained from individuals allergic to birch pollen. All patients suffered from rhinoconjunctivitis during spring, and none of them had allergic asthma and atopic dermatitis. Moreover, allergy was documented by positive skin prick reactions and allergen-specific IgE levels of >3.5 kU/L (ImmunoCAP; Thermo Fisher Scientific, Uppsala, Sweden). Nonallergic individuals had neither allergic symptoms nor specific IgE levels. The study had been approved by the local medical ethics committee, and informed written consent was obtained from all individuals.

Allergen uptake

Monocytes (2 × 10⁵) isolated by anti-CD14-coated magnetic beads (Miltenyi Biotec, Bergisch-Gladbach, Germany) were incubated with pHrodo-labeled Bet v 1 (3 µg/ml) in the presence or absence of TLR ligands. After 14 h, cells were counter-stained with fluorescence-labeled mAb specific to CD14 (BD Biosciences, San Jose, CA, USA), HLA-DR (BioLegend, San Diego, CA, USA), or the respective isotype controls and analyzed by flow cytometry.

Monocyte-derived dendritic cells

Monocyte-derived dendritic cells (mdDC) were generated from isolated monocytes by incubation with IL-4 and GM-CSF as described (20). Immature mdDC (1 × 10⁵ well) were either left untreated or stimulated with Pam3CSK4, FSL-1, LPS, MPL-A, or flagellin in 96 well plates (Nunclon; Nunc, Copenhagen, Denmark). After 48 h, cells were incubated with 20% human AB serum in PBS containing 0.1% BSA and 0.1% NaN₃ for 20 min at 4°C. Thereafter, cells were stained with fluorescence-labeled mAb specific to CD80, CD83, CD86, CD40, HLA-DR (all from BD Biosciences), and CCR7 (BioLegend). Anti-CD58 and anti-PD-L1 mAb were detected with a PE-conjugated anti-mouse IgG Ab (BioLegend). Respective isotype controls were done in parallel. Flow cytometry was performed with a FACS Canto (BD Biosciences) and evaluated by FLOWJO software v10 (Treestar Inc., Ashland, OR, USA). Cytokine levels were determined in supernatants (SN) harvested after 48 h using the Lumines System 100 (Luminex, Austin, TX, USA).
For mixed leukocyte reactions, mdDC were stimulated with TLR ligands for 48 h and irradiated (60 Gy), and allogeneic PBMC \((1 \times 10^5)\) were added in UltraCulture medium (Lonza, Basel, Switzerland) supplemented with 2 mM L-glutamine and 2 \(\times 10^{-5}\)M 2-mercaptoethanol for 6 days. Proliferation was assessed by the addition of [\(^3\)H]-thymidine (New England Nuclear Corp GmbH, Vienna, Austria; 0.5 \(\mu\)Ci/well) during the last 16 h of culture. All samples were analyzed in triplicate.

**Stimulation of naive CD4\(^+\) T cells**

Naïve CD4\(^+\) T cells were purified from PBMC using the Naïve CD4\(^+\) T cell Isolation Kit II (Miltenyi Biotec), resulting in >90% CD4\(^+\)CD45RA\(^+\) cells. CD4\(^+\)CD45RA\(^+\) T cells \((1 \times 10^5)\) were mixed with irradiated autologous mdDC \((1 \times 10^5)\) that had been stimulated with TLR ligands for 24 h. After 6 days, SN was collected and proliferation was assessed by the addition of [\(^3\)H]-thymidine for 16 h. Cytokine levels in SN were analyzed using the Lumex System 100. For intracellular cytokine detection, naïve CD4\(^+\) T cells \((1 \times 10^5)\) were mixed with irradiated, allogeneic mdDC \((1 \times 10^5)\) prestimulated with TLR ligands for 16 h. After 6 days, these T cells were re-stimulated with freshly isolated TLR-ligand-activated mdDC and, after another 6 days, activated with PMA (1 ng/ml), ionomycin (1.25 \(\mu\)M), and brefeldin A (10 \(\mu\)g/ml) for 5 h. Cells were stained with fixable viability dye eFluor\(^{TM}\) 506 (eBioscience Inc., San Diego, CA, USA), then fixed, permeabilized and stained with fluorescence-labeled mAb specific to IL-4 (BioLegend), CD4, IL-13 (both from BD Biosciences), IL-10, and IFN-\(\gamma\) (both from eBioscience Inc.) or the respective isotype controls as described (21).

**Statistics**

Statistical data analysis was performed using IBM SPSS Statistics 20 (SPSS, Chicago, IL, USA). Data were not normally distributed according to the Shapiro–Wilk test. Differences according to the Wilcoxon signed rank test were considered statistically significant for values of \(P < 0.05\).

**Results**

**Effects of TLR stimulation on allergen uptake by antigen-presenting cells**

We first investigated the effects of TLR ligands on allergen uptake as a prerequisite for the loading of MHC class II molecules with allergen-derived peptides. Because TLR-ligand-matured mdDC showed the expected lower capacity to internalize antigens than immature mdDC (data not shown), purified CD14\(^+\) cells were incubated with Bet v 1 in the absence or presence of Pam3CSK4 (100 nM), FSL-1 (100 nM), LPS (50 nM), MPL-A (50 nM), or flagellin (3 nM). These concentrations had been determined to give highest levels of mdDC maturation, that is, highest upregulation of CD83, for each TLR ligand in pilot experiments (data not shown), and were used throughout the study. Monocytes responded to LPS, FSL-1, or Pam3CSK4 with a clearly enhanced uptake of the major birch pollen allergen (Fig. 1A). MPL-A only slightly increased internalization of Bet v 1, whereas flagellin had no effect on allergen uptake. All TLR ligands similarly induced activation of monocytes as demonstrated by HLA-DR upregulation (Fig. 1B).

**Figure 1** Effects of TLR ligands on allergen uptake. (A) Purified CD14\(^+\) cells were incubated with pHrodo-labeled Bet v 1 (3 \(\mu\)g/ml) without/with Pam3CSK4 (100 nM), FSL-1 (100 nM), LPS (50 nM), MPL-A (50 nM), or flagellin (3 nM). One of four separate experiments with similar results is shown.

**Figure 1** Effects of TLR ligands on allergen uptake. (A) Purified CD14\(^+\) cells were incubated with pHrodo-labeled Bet v 1 (3 \(\mu\)g/ml) without/with Pam3CSK4 (100 nM), FSL-1 (100 nM), LPS (50 nM), MPL-A (50 nM), or flagellin (3 nM). One of four separate experiments with similar results is shown.
Phenotypic and functional maturation of mdDC in response to different TLR ligands

Monocyte-derived dendritic cells from five allergic individuals were stimulated with Pam3CSK4, FSL-1, LPS, MPL-A, or flagellin. Compared to medium alone, all TLR ligands significantly enhanced the expression of CD80, CD83, CD86, CCR7, and PD-L1 ($P < 0.05$, Fig. 2A). Pam3CSK4, FSL-1, LPS, and MPL-A significantly upregulated the expression of CD40, whereas only TLR4 ligands significantly enhanced CD58. TLR4 ligands induced a significantly higher expression of all surface molecules than TLR2 ligands and flagellin. TLR2 ligands and flagellin had similar effects. FSL-1 (TLR2/6) induced significantly higher expression of CD86 and PD-L1 than Pam3CSK4 (TLR1/2).

To test their functional capacity, TLR-ligand-activated mdDC were co-cultured with allogeneic PBMC. Consistent with the expression of co-stimulatory molecules, mdDC treated by TLR4 ligands and FSL-1 induced the strongest proliferative responses, followed by Pam3CSK4 and flagellin (Fig. 2B).

Cytokine responses of mdDC in response to different TLR ligands

We analyzed the production of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and different members of the IL-12 family (IL-12p70, IL-23, and IL-27) as well as IL-10 by mdDC stimulated with the different TLR ligands. Distinct response patterns to the different TLR ligands were found (Fig. 3). TLR4 ligands induced the production of IL-6, TNF-α, IL-12p70, and IL-10 but not of IL-1β, IL-23, and IL-27. In all experiments, LPS was a more potent inducer of cytokine synthesis than MPL-A. TLR2 ligands clearly enhanced the synthesis of IL-1β, IL-6, TNF-α, IL-12p70, IL-23, IL-27, and IL-10. Except for IL-6 and TNF-α, Pam3CSK4 was the more potent stimulus than FSL-1. Similar to TLR2 ligands, flagellin induced all cytokines under investigation.
Effects of TLR-ligand-activated mdDC on naive CD4+ T cells

TLR-ligand-preactivated mdDC from eight allergic donors were incubated with naive T cells, and proliferative and cytokine responses were assessed after 6 days (Fig. 4A,B). MdDC matured with all TLR ligands except Pam3CSK4 induced significant T-cell proliferation. As expected, LPS-matured mdDC promoted strong IFN-γ synthesis and low levels of IL-5 and IL-13, characteristic for a Th1-like response. In contrast, T-cell responses to mdDC matured with MPL-A and FSL-1 were characterized by significantly lower levels of IFN-γ and significantly higher levels of Th2 cytokines. Pam3CSK4-treated mdDC induced low levels of Th2 cytokines and negligible amounts of IFN-γ, whereas mdDC treated with flagellin promoted the synthesis of IFN-γ and the highest levels of both IL-5 and IL-13. Similar results were obtained with naive T cells and mdDC derived from three nonallergic individuals (data not shown). IL-4, IL-10, and IL-17 were not detectable in any of the cultures.

To detect IL-4 and IL-10 production as well as possible differences in the Th-cell subsets differentiated by different TLR-ligand-activated mdDC, we intracellularly stained for these cytokines, IL-13 and IFN-γ in T cells from four allergic patients. IL-4^IFN-γ^ and IL-13^IFN-γ^ cells were defined as Th2-like, IL-4^IFN-γ^ and IL-13^IFN-γ^ cells as Th0-like and IL-4^IFN-γ^ and IL-13^IFN-γ^ cells as Th1-like cells, respectively. Figure 4C shows that mdDC matured with all TLR ligands induced Th1-like cells though to a varying degree (LPS>MPL-A>FSL-1>flagellin>Pam3CSK4). LPS-matured mdDC exclusively promoted Th1-like responses, whereas mdDC stimulated with MPL-A, Pam3CSK4, FSL-1, or flagellin also primed Th0-like cells. The strongest induction of Th0-like cells was observed in response to Pam3CSK4 and flagellin. These TLR ligands and to a lower extent also FSL-1 induced Th2-like cells. IL-10 could not be detected in any of the cultures (data not shown).

Discussion

To avert the development of allergen-specific Th2 responses in atopic individuals is an important strategy in the prevention and cure of IgE-mediated allergic disorders. Here, we assessed the T-cell-polarizing capacity of ligands for TLR1/2, TLR2/6, TLR4, and TLR5, which are expressed on the surface of myeloid DC, macrophages, and Langerhans cells located in the skin, that is, at the site of vaccine injection. We deliberately used the concentration of each TLR ligand that induced highest levels of mdDC maturation as fully matured DC are a prerequisite for the successful induction of Th1 responses in vivo (22). Under these conditions, all TLR ligands instructed mdDC to induce IFN-γ-producing T cells (23). However, analyses at the single cell level revealed clear differences in the obtained T-cell subsets: LPS-treated mdDC promoted solely Th1 cells while mdDC activated by MPL-A, FSL-1, Pam3CSK4, and flagellin also induced Th0-like cells that concomitantly produced Th2 cytokines and IFN-γ. Only mdDC matured with flagellin, Pam3CSK4 and to a lower extent with FSL-1 additionally induced Th2 cells. Priming of Th2 responses accorded with a less pronounced upregulation of CD40, CD80, CD86, CD58, and PD-L1, a limited production of IL-6 and TNF-α, and an enhanced synthesis of IL-1β, IL-23, and IL-27 by mdDC. Recently, it has been reported that TLR4-induced IL-1β and not IL-27 significantly enhanced the production of IL-13 in PBMC (24). Along these lines, our data provide evidence that IL-1β may also be an important cytokine for the polarization of naive T cells toward Th2 responses. It has been observed previously.
that Pam3CSK4 instructs human DC to induce Th2 responses (25), and there is evidence for a Th2-promoting capacity of flagellin in mice (26, 27). In addition, patients with allergic asthma showed significantly higher titers of flagellin-specific antibodies compared with healthy controls (26). Furthermore, human keratinocytes have been shown to produce thymic stromal lymphopoietin (TSLP), a Th2-promoting cytokine, in response to flagellin (28). These studies already suggested a role for flagellin as risk factor for asthma and atopic dermatitis. Our study is first to demonstrate the induction of human Th2 cells by flagellin. Notably, flagellin also promoted Th2 polarization in naive T cells derived from three nonallergic individuals (data not shown), indicating that the Th2-promoting capacity of flagellin is not restricted to the atopic status. Moreover, we noted that FSL-1 targeting TLR2/6 elicited effects distinct from Pam3CSK4 targeting TLR1/2. Pam3CSK4 more potently induced IL-10, IL-12p70, IL-23, and IL-27 than FSL-1. On the other hand, FSL-1 induced a significantly higher expression of CD86 and PD-L1, higher proliferative responses of allogeneic PBMC as well as a more pronounced production of IL-6 and TNF-α than Pam3CSK4. On the other hand, FSL-1 induced a significantly higher expression of CD86 and PD-L1, higher proliferative responses of allogeneic PBMC as well as a more pronounced production of IL-6 and TNF-α than Pam3CSK4. Together, these effects translated into a stronger induction of Th1-like cells by FSL-1 than by Pam3CSK4. Hence, we provide first evidence that stimulation of distinct TLR2 heterodimers has divergent effects on innate APC and subsequent differentiation of T cells from allergic patients.

Besides co-stimulatory molecules and cytokines, the mode of activation of the T-cell receptor influences T-cell polarization. A higher density of MHC class II complexes loaded with antigen-derived peptides on the surface of APC has been demonstrated to promote Th1-like responses whereas a lower density supported Th2-like responses (29). We found that LPS and FSL-1 strongly enhanced allergen uptake whereas Pam3CSK4 and MPL-A showed weaker effects. Flagellin only marginally affected allergen uptake of APC. Thus, the Th1-polarizing activity of the different TLR ligands accorded with enhanced endocytosis of allergen except for MPL-A. In addition to signal 2 and 3, also signal 1 for T-cell activation seemed to be differently regulated by TLR ligands targeting distinct TLR2-heterodimers, as FSL-1 and Pam3CSK4 showed diverse effects on the uptake of allergen.

Collectively, we found that agonists of TLR4 and TLR5 and the heterodimers TLR1/2 and TLR2/6 exert divergent T-cell-polarizing activities that result from differential effects on APC. In all cases, TLR4 ligands were significantly more effective than TLR2 and TLR5 ligands. Regarding TLR4 and TLR2 ligands, this observation accords with Agrawal
et al. (25) who have studied mDC from nonallergic individuals. Divergent modes of activation of human DC have been reported for TLR2 and TLR4 ligands (30). In contrast to TLR2 ligands, TLR4 agonists induced the chemokine IFN-inducible protein (IP)-10 and IL-12 p70, which are both associated with Th1-like responses. We also found marked differences between TLR4 and TLR2 ligands. Whereas TLR4 ligands were stronger inducers of IL-6, TNF-α, IL-12 p70, and IL-10 synthesis by mDC, solely TLR2 ligands induced the production of IL-1β, IL-23, and IL-27. In our experimental setup, we could not detect IL-10-producing T cells in response to TLR-ligand-activated mDC which may be referred to the use of fully matured mDC.

Our in vitro analyses in allergic patients attest that different TLR ligands should be considered in the design of improved allergy vaccines. Possibly, TLR ligands that promote the differentiation of IL-4/IFN-γ+ T cells may have the advantage of not exclusively promoting potentially harmful Th1-like immune responses. The assessment of regulatory effects is still technically challenging. For definitive statements on the suitability of TLR ligands as adjuvants, the different aspects of their effects need to be addressed in humans in vivo.

Acknowledgments

The work was supported by the Austrian Science Fund, project FWF-SFB-F4610, the Christian Doppler Research Association and Biomay AG, Vienna, Austria.

Author contributions

S.D., C.K., B.J.S., and B.B. designed the experiments; S.D., C.K., and M.H. performed the experiments and analyzed the data; P.S. provided Abs and helped with data analyses; G.F.F. performed HLA typing; G.J.Z. performed cytokine analyses; S.D. and B.B. wrote the manuscript.

Conflicts of interest

The authors declare no competing financial interests.

References

1. Ebner C, Schenk S, Najatli N, Siemens U, Steiner R, Fischer GW et al. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995;154:1932–1940.
2. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannis D, Cramer R et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567–1575.
3. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6:761–771.
4. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133–146.
5. Brombacher F, Kastelijn RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 2003;24:207–212.
6. Smits HH, van Beelen AJ, Hesse C, Westland R, de Jong E, Soeteman E et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 2004;34:1371–1380.
7. Medzhitov R. Approaching the asymptote: 20 years later. Immunity 2009;30:766–775.
8. Drachenberg KJ, Wheeler AW, Stuehrner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498–505.
9. Drachenberg KJ, Heinzkiß M, Urban E, Wornecke SR. Efficiency and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 2003;31:270–277.
10. Pfaar O, Barth C, Jäschke C, Horrrmann K, Klimek L. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2010;154:336–344.
11. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. Immunotherapy with a rag-weed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445–1455.
12. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005;60:678–684.
13. Bohle B, Jahn-Schmid B, Maurer D, Kraft D, Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 1999;29:2344–2353.
14. Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R et al. Tolerance induction after specific immunotherapy with pollen allergens adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol 2010;160:403–410.
15. Musarza A, Bignardi D, Troise C, Passalacqua G. Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to birterata. A controlled field study. Eur Ann Allergy Clin Immunol 2010;42:115–119.
16. Terhorst D, Kalali BN, Weidinger S, Ilig T, Novak N, Ring J et al. Monocyte-derived dendritic cells from highly atopic individuals are not impaired in their pro-inflammatory response to toll-like receptor ligands. Clin Exp Allergy 2007;37:381–390.
17. Wakkach A, Cottrez F, Groux H. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol 2001;167:3017–3023.
18. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001;193:839–846.
19. Kitzmuller C, Nagl B, Deifl S, Walterskirchen C, Jahn-Schmid B, Zlabinger GJ et al. Human blood basophils do not act as antigen-presenting cells for the major birch pollen allergen Bet v 1. Allergy 2012;67:593–600.
20. Mutschlechner S, Egger M, Briza P, Wallner M, Lackner P, Karle A et al. Naturally processed T cell-activating peptides of the major birch pollen allergen. J Allergy Clin Immunol 2010;125:711–718.
21. Gerstmayr M, Ilk N, Jahn-Schmid B, Sleytr UB, Bohle B. Natural self-assembly of allergen-S-layer fusion proteins is no prerequisite for reduced allergenicity and T cell stimulatory capacity. Int Arch Allergy Immunol 2009;149:231–238.
22. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006;108:1435–1440.
23. Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. *Immunol Lett* 2009; 125:114–118.

24. Kucuksezer UC, Palomares O, Ruckert B, Jartti T, Puhakka T, Nandy A et al. Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. *J Allergy Clin Immunol* 2013; 131:875–885.

25. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. *J Immunol* 2003; 171:4984–4989.

26. Wilson RH, Maruoka S, Whitehead GS, Foley JF, Flake GP, Sever ML et al. The Toll-like receptor 5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens. *Nat Med* 2012; 18:1705–1710.

27. Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, Carlsen H et al. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. *J Immunol* 2004; 172:6922–6930.

28. Le TA, Takai T, Vu AT, Kinoshita H, Chen X, Ikeda S et al. Flagellin induces the expression of thymic stromal lymphopoietin in human keratinocytes via toll-like receptor 5. *Int Arch Allergy Immunol* 2011; 155:31–37.

29. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. *J Exp Med* 1995; 182:1591–1596.

30. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. *J Biol Chem* 2001; 276:37692–37699.